Following the 2023 San Antonio Breast Cancer Symposium, Hope Rugo, MD joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss key clinical trial data updates in HR+, HER2- Breast Cancer.
EP. 1: Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer
Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.
EP. 2: MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer
Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.
EP. 3: Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer
Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.
EP. 4: TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer
Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.
EP. 5: Key Takeaways from SABCS 2023
Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in HR+/HER2- breast cancer.
2 Commerce Drive Cranbury, NJ 08512